Analysts Downgrade These Healthcare Stocks in Last Week of November: VRUS, GILD, POZN

Wall St. Watchdog reveals information about companies for which stock analysts downgraded shares in the Healthcare sector for the week ending November 25th, 2011.

  • Pharmasset (NASDAQ:VRUS): Brean Murray downgraded its rating on this company from Buy to Hold. Canaccord Genuity downgraded its rating on this company from Buy to Hold on Nov 22nd. The shares recently traded at $133.17, down $0.26, or 0.19% since the analyst’s rating. About the company: Pharmasset, Inc. is a pharmaceutical company. The Company develops oral therapeutics for the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV). Get the most recent company news and stock data here >>
  • Gilead Sciences (NASDAQ:GILD): Summer Street Research downgraded its rating on this company from Buy to Neutral on Nov 22nd. The shares recently traded at $39.80, up $1.04, or 2.68% since the analyst’s rating.  Argus downgraded its rating on this company from Buy to Hold on Nov 23rd. The shares recently traded at $39.80, up $0.16, or 0.4% since the analyst’s rating.  About the company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Get the most recent company news and stock data here >>
  • POZEN (NASDAQ:POZN): Brean Murray downgraded its rating on this company to Buy and changed its price target from $9 to $7 on Nov 25th. The shares recently traded at $3.81, up $0.19, or 5.25% since the analyst’s rating. About the company: POZEN Inc. is a pharmaceutical company that develops therapeutics for diseases with unmet medical needs. The Company’s product candidates include migraine treatments as well as is exploring the development of product candidates in other pain-related therapeutic areas. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet